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Can recombinant growth 
hormone effectively treat 
idiopathic short stature?
Yes, treatment can increase a child’s fi nal 
height. Injections of recombinant human 
growth hormone (rGH) at least 3 times a 
week for 4 to 6 years add 3.7 to 7.5 cm to 
fi nal height in children between 8 and 16 
years of age with idiopathic short stature 
(strength of recommendation [SOR]: B, 2 
small, low-quality, randomized controlled 
trials [RCTs]). This population comprises 
children who are otherwise physically 
and developmentally normal with a 
height standard deviation score (SDS) of 
≤−2.0—comparable to the bottom 2.5% 
percentile of height—and an adequate 
response to growth hormone stimulation 
testing. 
Evidence-based answer
Clinical commentary
Do we really want to treat 
healthy short children?
Parents should understand that children 
who are treated with rGH will still be 
short, just less short. A young man with 
a predicted adult height of 63 inches 
after 5 years will have an adult height of 
65 inches—still short by most measures. 
Clinical trials of rGH for idiopathic short 
stature have been small and of poor 
quality, raising the possibility of unforeseen 
serious adverse outcomes. 
 Families need to know that insurance 
rarely covers treatment, which costs 
$100,000. Treating all of the 400,000 
children in the United States with 
idiopathic short stature would cost 
$40 billion. Moreover, treating healthy 
short children with rGH raises questions 
about the value of height and physical 
appearance, which are even more diffi cult 
to address. 
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❚ Evidence summary
rGH has been available since 1985. The 
Food and Drug Administration has ap-
proved it for such conditions as growth 
hormone defi ciency, chronic renal in-
suffi ciency, Turner syndrome, small size 
for gestational age, and Prader-Willi 
syndrome.1 The use of rGH to treat id-
iopathic short stature introduces many 
clinical, economic, and ethical questions. 
We have attempted to discern the clinical 
effectiveness of treatment by focusing on 
RCTs of rGH therapy while leaving the 
other substantive issues unexplored.
Final height is arguably the most im-
portant outcome measure for the effects 
of rGH and may be represented as actual 
height or as a standard deviation score 
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Children treated 
with rGH will still 
be short—just less 
short
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(SDS)—actual height minus mean height 
for age divided by standard deviation of 
height for age.2 This measure standard-
izes height comparisons for different age 
groups and is comparable to the percen-
tile values on growth charts. 
Growth hormone increases 
height in girls and boys
A 2003 Cochrane systematic review iden-
tifi ed 9 RCTs that evaluated treatment 
with rGH in children with idiopathic 
short stature. Only 1 used near fi nal 
height as its main outcome. Inclusion cri-
teria for this RCT comprised prepubertal 
girls in the bottom third percentile for 
height without a known cause. 
Of the 40 subjects, only 18 provid-
ed consent for randomization. Seven of 
the 10 girls randomized to the treatment 
group and 6 of the 8 randomized to the 
control group completed the study to fi -
nal height measurement. The average age 
of the treated girls at the start of therapy 
was 8.07 years; the average duration of 
treatment was 6.2 years. All participants 
reached stage 4 breast development, men-
arche, and a growth velocity of <2 cm 
per year in the year preceding fi nal height 
measurement. Mean fi nal height in the 
treatment group was 155.3 cm compared 
to 147.8 cm in the control group—a
7.5-cm difference (95% confi dence inter-
val [CI], 3.14-11.86 cm).2,3 
A double-blind, placebo-controlled 
RCT published after the Cochrane review 
assessed fi nal height in a peripubertal, pre-
dominantly male population with non-
growth-hormone-defi cient short stature.4 
Inclusion criteria comprised a height SDS 
<−2.50, but 6 participants with a height 
SDS between −2.25 and −2.5 were in-
cluded because of a change in the crite-
ria.5 Sixty-eight children were initially 
randomized. Of the 37 randomized to 
treatment, 22 were available for fi nal 
height measurement. The placebo group 
had a higher dropout rate—only 11 of 
31 patients were available for fi nal height 
measurement. In an attempt to reduce 
the dropout rate, the fi nal height criteri-
on for discontinuation of injections was 
changed from <0.5 to <1.5 cm per year. 
The mean age of the treatment group 
was 12.5 years at initiation of treatment; 
average duration of treatment was 4.6 
years. 
Intent-to-treat analysis of patients 
who received at least 6 months of treat-
ment with fi nal height assessment re-
vealed a positive treatment effect on 
height (SDS) of 0.51. This is the equiva-
lent of a 3.7-cm difference in fi nal height 
for the treatment group compared with 
the placebo group (P<.02; 95% CI, 0.10-
0.92 SDS).5
Recommendations 
The FDA has approved rGH for use in 
children with height SDS ≤−2.25—equiv-
alent to the lowest 1.2% of children. The 
Lawson-Wilkins Pediatric Endocrinology 
Society Drug and Therapeutics Commit-
tee states that rGH therapy should be 
considered only after accurate diagnosis, 
careful monitoring of growth velocity, 
and estimation of fi nal height by a pedi-
atric endocrinologist.6,7 ■
References
 1.  Weise KL, Nahata MC. Growth hormone use in chil-
dren with idiopathic short stature. Ann Pharmaco-
ther. 2004;38:1460-1468.
 2.  Bryant J, Cave C, Milne R. Recombinant growth 
hormone for idiopathic short stature in children 
and adolescents. Cochrane Database Syst Rev. 
2003;(2):CD004440. 
 3.  McCaughey ES, Mulligan J, Voss LD, et al. Ran-
domised trial of growth hormone in short normal 
girls. Lancet. 1998;351:940-944.
 4.  Leschek EW, Rose SR, Yanovski JA, et al. Effect of 
growth hormone treatment on adult height in peri-
pubertal children with idiopathic short stature: a 
randomized, double-blind, placebo-controlled trial. 
J Clin Endocrinol Metab. 2004;89:3140-3148.
 5.  Humatrope for non-growth-hormone-defi cient 
short stature. Briefi ng document from the Endocri-
nologic and Metabolic Drugs Advisory Committee. 
Lilly Research Laboratories, Eli Lilly and Company, 
Indianapolis, IN, June 10, 2003, volume 1. 
 6.  FDA approves Humatrope for short stature. Avail-
able at: www.fda.gov/bbs/topics/ANSWERS/2003/
ANS01242.html. Accessed June 12, 2008. 
 7.  Wilson TA, Rose SR, Cohen P, et al. Update of 
guidelines for the use of growth hormone in chil-
dren: the Lawson Wilkins Pediatric Endocrinology 
Society Drug and Therapeutics Committee. J Pedi-
atr. 2003;143:415-421.
rGH treatment 
is expensive and 
rarely covered 
by insurance 
612_JFP0908   612 8/18/08   2:14:56 PM
